Recon: Shape Therapeutics' $112M gene therapy play; Incyte's cancer drug flops at FDA

ReconReconAdvertising, Promotion and LabelingBiologics/ biosimilars/ vaccinesBiotechnologyClinical TrialsComplianceEthicsGlobalHealth Authority meeting and communication strategyMedical DevicesPharmaceuticalsPreclinical studyQuality Assurance and ControlRegulatory Intelligence/PolicyResearch, Design and DevelopmentSupply Chain Management